Grading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples

Sadeleştirilmiş öğe sayfası
dc.contributor.authorMahoney, Liam
dc.contributor.authorRaffaeli, Genny
dc.contributor.authorBeken, Serdar
dc.contributor.authorUnal, Sezin
dc.contributor.authorKotidis, Charalampos
dc.contributor.authorCavallaro, Giacomo
dc.contributor.authorGarrido, Felipe
dc.contributor.authorBhatt, Aomesh
dc.contributor.authorDempsey, Eugene M.
dc.contributor.authorAllegaert, Karel
dc.contributor.authorSimons, Sinno H. P.
dc.contributor.authorFlint, Robert B.
dc.contributor.authorSmits, Anne
dc.contributor.authorESPR Pharmacology Section
dc.date.accessioned2025-10-16T15:14:34Z
dc.date.issued2024
dc.identifier.doi10.1038/s41390-023-02779-9
dc.identifier.otherWOS:001070817300001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6211
dc.publisherSPRINGERNATURE
dc.sourcePEDIATRIC RESEARCH
dc.titleGrading the level of evidence of neonatal pharmacotherapy: midazolam and phenobarbital as examples
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS